Novogene Announces Deployment of Illumina NovaSeq™ X Plus and PacBio REVIO Sequencing Systems
SINGAPORE,Jan. 5,2023 --Novogene,a leading provider of genomic services and solutions,announced the addition of Illumina's latest high-throughput sequencing system NovaSeq™ X Plus and PacBio's Revio™ long-read sequencing system to its lineup of sequencing platforms. These systems will be deployed in Novogene's regional lab facilities and will be available to its global customer base.
Novogene is a trusted genomics partner to scientists worldwide and provides access to the latest genomics tools to the scientific community. The acquisition of these new platforms is expected to enhance Novogene's capabilities and quality of genomics research services,allowing its customers to handle higher throughput and more ground-breaking research.
NovaSeq™ X Plusis Illumina's high-throughput sequencing system that delivers the best performance in terms of throughput,production capacity and sustainability. It has a throughput of up to 2.5 times that of prior sequencers,and cangeneratemorethan20,000wholegenomesperyear,making it ideal for large-scale sequencing projects and ambitious genomics studies. It has the potential to drive down the cost of sequencing and accelerate the adoption of DNA sequencing technologies in a variety of research and clinical applications.
Pacbio'sRevio long-read sequencing platform provides customers with the ability to sequence up to 1,300 human whole genomes per year at 30-fold coverage. The platform runs up to four SMRT Cells in parallel,which provides up to 100 million zero-mode waveguides (ZMWs) for sequencing single molecules simultaneously. Combined with the significant advance in PacBio's computing capability,Revio is on track to deliver a shorter runtime and a 15-fold increase in HiFi data.
"Over the past decade,Novogene has been driving genomics innovation by providing comprehensive sequencing solutions to the scientific community. We have witnessed significant advances in the field of genomics and recognise that in order to continue making new breakthroughs and discoveries,we need to have access to more powerful,faster and cost-effective platforms. We have used both Illumina's HiSeq2000 and PacBio's Sequel as well as all the later generation sequencing systems introduced by these companies. We are very excited about the release of new sequencing platforms by our partners," said Dr. Ruiqiang Li,founder and CEO of Novogene. "Novogene will also continue to actively develop new applications and sequencing solutions as part of our efforts to expand the range of use cases on these latest platforms,as we believe that we can push the frontier of genomics research and deliver critical insights to diseases,through working together with our partners."
As of 2022,Novogene has established 7 lab facilities globally,serving a customer base of over 6,100 institutions,including scientific research organisations,universities,hospitals,pharmaceutical companies,and agribusinesses. The company has also co-published and/or been acknowledged in over 16,000 articles in Science Citation Index,with an accumulative impact factor nearing 100,000.
In 2023,Novogene is well positioned to continue driving innovation and upgrading its products to support global research,development,and application of life sciences solutions,with the aim of fulfilling its mission of "Advancing Genomics,Improving Life".
About Novogene
Novogene is a pioneer in applying cutting-edge molecular biology technology and high-performance computing to research in the fields of life science and human health. Our vision is to continue as a global leader in the delivery of genomics services and solutions.
With one of the largest sequencing capacities in the world,we utilise our deep scientific knowledge,first-class customer service and unsurpassed data quality to help clients realise their research goals in the rapidly evolving world of genomics. Novogene is committed to become your trusted genomics partner.
